"Quintiles is excited about the progress made by PACeR toward speeding up clinical trials through more rapid patient recruitment and enrollment, and a reduced need for protocol amendments," said John Murphy, Head, Clinical Analytics in Consulting at Quintiles, and project manager for PACeR. "In addition to the benefit to patients of earlier access to innovative therapies, this could bring multi-million dollar savings to our biopharma customers as they work to respond to ever-changing conditions in the New Health, where managing risk is a constant."
New PACeR Participants Welcome
Ad Statistics
Times Displayed: 2548
Times Visited: 12 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
PACeR strongly encourages participation of additional members in Phase 2, and welcomes the perspectives of new members such as physician professional societies, community hospitals, device manufacturers, EMR vendors, disease societies, and others. The more comprehensive PACeR's membership, the more sustainable its approach becomes.
Back to HCB News
